source
- This week in charts: Biotech investors’ China bets are already paying offThis year, companies built around medicines from China have sped toward acquisitions or IPOs. Meanwhile, Summit is no longer the Wall Street darling it was in 2024.BioPharma Dive · 1h ago↗ source
- US panel warns China’s biotech plan could dominate sector and threaten drug supply chainA congressional commission has warned that China’s new five-year biotech plan could allow it to dominate the global drug market. The commission says the strategy could leave U.S. patients vulnerab…